TRCT
HCWB icon

Tower Research Capital (TRC)’s HCW Biologics HCWB Stock Holding History

Tower Research Capital (TRC)’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5K Buy
4,117
+1,644
+66% +$9.32K ﹤0.01% 3531
2026
Q1 		$5.34K Buy
2,473
+1,722
+229% +$8.9K ﹤0.01% 4125
2025
Q4 		$4.37K Buy
751
+491
+189% +$8.34K ﹤0.01% 4224
2025
Q3 		$5.78K Buy
260
+218
+519% +$5.7K ﹤0.01% 4201
2025
Q2 		$991 Buy
+42
New +$1.83K ﹤0.01% 4892
2025
Q1 		– Sell
-7
Closed -$615 – 5109
2024
Q4 		$797 Sell
7
-18
-72% -$2.1K ﹤0.01% 5165
2024
Q3 		$3.17K Sell
25
-1
-4% -$136 ﹤0.01% 4889
2024
Q2 		$4.02K Buy
26
+5
+24% +$1.48K ﹤0.01% 4829
2024
Q1 		$8.64K Sell
21
-3
-13% -$959 ﹤0.01% 3986
2023
Q4 		$6.95K Buy
24
+5
+26% +$1.71K ﹤0.01% 4682
2023
Q3 		$8.86K Buy
19
+4
+27% +$1.98K ﹤0.01% 4293
2023
Q2 		$8.01K Sell
15
-18
-55% -$7.16K ﹤0.01% 4486
2023
Q1 		$11K Buy
33
+5
+18% +$2.17K ﹤0.01% 4222
2022
Q4 		$13K Buy
28
+1
+4% +$517 ﹤0.01% 3609
2022
Q3 		$15K Buy
27
+12
+80% +$6.88K ﹤0.01% 4167
2022
Q2 		$8K Buy
15
+12
+400% +$6.74K ﹤0.01% 4677
2022
Q1 		$2K Buy
+3
New +$1.6K ﹤0.01% 5555
2021
Q4 		– Sell
-24
Closed -$18K – 6307
2021
Q3 		$18K Buy
+24
New +$25.2K ﹤0.01% 3823

Other funds holding HCWB

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s HCWB Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its HCW Biologics (HCWB) stake by 66% in Q2 2026, buying an estimated $9.32K and bringing the position to 4,117 shares worth $20.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3531.

Tower Research Capital (TRC) first reported a position in HCWB in Q3 2021 and has held it in 18 quarters since. 8 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • Tower Research Capital (TRC) held 4,117 shares of HCW Biologics worth $20.5K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,644 HCW Biologics shares in Q2 2026, an estimated $9.32K.
  • HCW Biologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3531 holding.
  • Tower Research Capital (TRC) first reported a position in HCW Biologics in Q3 2021 and has held it in 18 quarters since.
  • 8 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.